Smoldering myeloma
According to the Mayo 2018 / IMWG 2/20/20 model.
Risk factor | Threshold |
Serum M-protein | >2 g/dL |
Involved/uninvolved free light chain ratio | >20 |
Bone marrow plasma cells | >20% |
High risk = at least 2 of these 3 criteria
Additional adverse features include del(17p), t(4;14), gain(1q), evolving M-protein, and certain MRI abnormalities. These can refine risk assessment.
Patients meeting the 2/20/20 high-risk criteria have approximately a 40–50% risk of progression to multiple myeloma
The phase 3 AQUILA trial demonstrated with daratumumab a 51% relative reduction in the risk of progression to active multiple myeloma or death compared with active monitoring
The ASCO 2026 living guideline recommends that patients with high-risk SMM may be offered either active monitoring or daratumumab for up to 36 months, using shared decision-making.


Comments